Todd B. Buck, Ph.D. counsels clients in all phases of patent law and portfolio management. He litigates and advises clients on worldwide biotechnology and pharmaceutical sciences in District Court litigation, patent interferences and other inter partes disputes before the US Patent and Trademark Office. He also provides opinions and advice on transactional matters, prepares and prosecutes utility patent applications before the US Patent and Trademark Office, and procures foreign patent rights internationally.
With a Ph.D. in pharmacology and toxicology, Todd counsels established and emerging growth companies on developing domestic and international biotech and chemical patent portfolios. As part of his counseling practice, he utilizes his in-depth understanding of the complexities of the pharmaceutical and biotechnology arts to develop freedom to operate, patentability, invalidity, infringement and non-infringement analyses, and assessments for his clients.
As a past post-doctoral position holder at the National Cancer Institute of the National Institutes of Health, Todd has experience in the generation and use of transgenic animals and other molecular and cell biology techniques to study the molecular mechanism of tumor initiation and growth, particularly angiogenesis. When working with biotech clients, he applies and relates this knowledge to advise on the best patent portfolio strategies.
Before joining Morgan Lewis, he was the founder and managing partner of a Washington, DC-based IP law firm, where he focused on practice portfolio management for pharmaceutical and biotechnology companies. He stays active in the IP area through frequent speaking engagements in the United States and abroad on US biotechnology IP law.
The George Washington University Law School, 2003, J.D.